These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States. Jethwa PR; Patel TD; Hajart AF; Eloy JA; Couldwell WT; Liu JK World Neurosurg; 2016 Mar; 87():65-76. PubMed ID: 26548828 [TBL] [Abstract][Full Text] [Related]
5. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Hamilton DK; Vance ML; Boulos PT; Laws ER Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069 [TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinemia: pathophysiology and management. Verhelst J; Abs R Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552 [TBL] [Abstract][Full Text] [Related]
7. [Some issues in the diagnosis and treatment of hyperprolactinemia]. Jin ZM Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959 [No Abstract] [Full Text] [Related]
8. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009 [TBL] [Abstract][Full Text] [Related]
11. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629 [TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinemia and prolactinomas. Mancini T; Casanueva FF; Giustina A Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731 [TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia and prolactinoma. Romijn JA Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588 [TBL] [Abstract][Full Text] [Related]
14. Medical treatment of prolactinomas. Molitch ME Endocrinol Metab Clin North Am; 1999 Mar; 28(1):143-69, vii. PubMed ID: 10207689 [TBL] [Abstract][Full Text] [Related]
15. Prolactin, prolactin disorders, and dopamine agonists during pregnancy. Levin G; Rottenstreich A Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577 [TBL] [Abstract][Full Text] [Related]
19. [Management of prolactinomas during pregnancy]. Chen W; Bian X; Gai M; Zhang Y Zhonghua Fu Chan Ke Za Zhi; 2002 Jun; 37(6):335-7. PubMed ID: 12126566 [TBL] [Abstract][Full Text] [Related]
20. Management of prolactinomas during pregnancy. Witek P; Zieliński G Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]